Alltrna, a Cambridge, MA-based company unlocking transfer RNA (tRNA) biology and pioneering tRNA medicines to regulate the protein universe and resolve disease, raised $109m in Series B financing.
The round included the company’s founder, Flagship Pioneering, and a number of top-tier investors.
The company intends to use the funds to advance its platform and first drug candidates towards the clinic for a first indication in Stop Codon Disease. Stop Codon Disease encompasses thousands of rare and common diseases that stem from premature termination codons (PTC) also called nonsense mutations, where the code for an amino acid has been mutated into a premature “stop” codon. This results in a truncated or shortened protein product with no or altered biological activity that causes disease. Approximately 10% of all people with a genetic disease have Stop Codon Disease, representing approximately 30 million people worldwide.
Alltrna is engineering tRNA medicines that can read these PTC mutations and deliver the desired amino acid, thereby restoring the production of the full-length protein.
Key people include:
- Michelle C. Werner, CEO of Alltrna and CEO-Partner of Flagship Pioneering,
- Lovisa Afzelius, Ph.D., MBA, Origination Partner at Flagship Pioneering and Co-Founder and Board Director
- Noubar Afeyan, Ph.D., Co-Founder and Chairperson of the Board of Alltrna and Founder and CEO of Flagship Pioneering
FinSMEs
09/08/2023